



> Return address PO Box 320, 1110 AH Diemen

Minister of Medical Care and Sports  
PO Box 20350  
2500 EJ THE HAGUE

2021026352

Date 26 July 2021  
Subject GVS advice on ferrimaltol (Feraccru®)

**National Health Care  
Institute**

Care  
Medicinal Products

Willem Dudokhof 1  
1112 ZA Diemen  
PO Box 320  
1110 AH Diemen  
[www.zorginstituutnederland.nl](http://www.zorginstituutnederland.nl)  
[info@zinl.nl](mailto:info@zinl.nl)

T +31 (0)20 797 85 55

**Contact**

Dr T.H.L. Tran  
T +31 (0)6 120 014 12

**Our reference**

2021026352

Dear Ms van Ark,

In your letter of 9 February 2021 (CIBG-21-01418), you asked the National Health Care Institute to assess whether the product ferrimaltol (Feraccru®) is interchangeable with another product that is included in the Medicine Reimbursement System (GVS). The National Health Care Institute, advised by the Scientific Advisory Board (WAR), has completed this assessment. The considerations are included in the pharmacotherapeutic report attached to this letter.

Feraccru® is available as a capsule containing 30 mg ferric ( $\text{Fe}^{3+}$ ) iron (as ferrimaltol) and is licensed for treating iron deficiency in adults. The treatment duration will depend on the severity of the iron deficiency, but treatment lasting at least twelve weeks is usually necessary. Treatment should be continued for as long as necessary to replenish the body's iron stocks as shown by blood tests.

The marketing authorisation holder is asking for inclusion in List 1B of the Health Insurance Regulation for a subpopulation of the licensed indication: Treatment of adults with mild to moderate iron deficiency anaemia who have previously failed with oral ferrous ( $\text{Fe}^{2+}$ ) iron preparations because of insufficient efficacy and/or intolerance.

**The outcome of the assessment**

The assessment compared ferrimaltol against intravenously administered iron. Due to the lack of evidence, no conclusions can be drawn about the beneficial and adverse effects of ferrimaltol compared to intravenously administered iron for the subpopulation mentioned above. The National Health Care Institute reached a final conclusion that ferrimaltol does not meet established medical science and medical practice when compared to intravenously administered iron for treating patients with inflammatory bowel disease with mild to moderate iron deficiency anaemia who are under treatment by a specialist and who cannot be treated with oral ferrous ( $\text{Fe}^{2+}$ ) iron.

**Advice**

The National Health Care Institute recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System.

**National Health Care  
Institute**  
Care  
Medicinal Products

**Future developments**

The National Health Care Institute is of course prepared to reassess the package eligibility of ferrimaltol (Feraccru®) if additional peer-reviewed research data not previously assessed by the National Health Care Institute becomes available.

**Date**  
26 July 2021

**Our reference**  
2021026352

Yours sincerely,

Tiana van Grinsven  
*Acting Chair of the Executive Board*